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Abstract: Renal transplant recipients (RTRs) often suffer from posttransplant diarrhea. The observed
dysbiosis in RTR may influence the fermentation processes in the gut. In this study, we aimed to
investigate whether fermentation differs between RTRs and healthy controls (HCs), by measuring
breath H2 and CH4 concentrations. Additionally, we determined the fecal presence of the methanogen
Methanobrevibacter smithii (M. smithii), which plays a main role in the process of methanogenesis.
Data from the TransplantLines Biobank and Cohort Study (NCT03272841) was used. A total of
142 RTRs and 77 HCs were included. Breath H2 concentrations in RTRs were not significantly different
from HCs. Breath CH4 concentrations in RTRs were significantly lower compared with HCs (median
[interquartile range (IQR)] 7.5 [3.9–10.6] ppm vs. 16.0 [8.0–45.5] ppm, p < 0.001). M. smithii was
less frequently present in the feces of RTRs compared to HCs (28.6% vs. 86.4% resp., p < 0.001).
Our findings regarding the altered methanogenesis in the gut of RTRs show similarities with previous
results in inflammatory bowel disease patients. These findings provide novel insight into the
alterations of fermentation after renal transplantation, which may contribute to understanding the
occurrence of posttransplant diarrhea.
Keywords: posttransplant diarrhea; methanogenesis; Methanosphaera stadtmanae; mucins; sulfate-
reducing bacteria
1. Introduction
Renal transplantation is the preferred treatment for patients with end-stage renal disease [1–3].
Part of its success has been made possible by improved therapeutic options, such as ameliorations in
surgical techniques and perioperative care [4]. Despite the success of transplantation, the burden of
morbidity in renal transplant recipients (RTRs) remains high [5].
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Patients often experience gastrointestinal complaints such as diarrhea, which is associated
with premature kidney allograft failure and mortality, and which affects quality of life [5,6].
This posttransplant diarrhea is believed to be non-infectious and induced by the use of medication [5,7].
Recently, a study in RTRs showed that dysbiosis in the gut might cause or contribute to this
posttransplant diarrhea [7]. Lee et al. demonstrated in this study that the gut microbiota diversity of
RTRs with diarrhea was significantly lower than in RTRs without diarrhea. In addition, RTRs with
diarrhea had a lower diversity of commensal bacterial taxa in the gut, creating a dysfunctional metabolic
state. These commensal bacterial taxa are important for the degradation of complex molecules such as
complex carbohydrates. During this degradation, among many other molecules, short-chain fatty acids
are produced, which contributes to overall gut health [8,9]. It has been proposed that posttransplant
diarrhea might be the consequence of a diminished ability to digest complex sugars [7]. A proportion
of complex polymers such as fibers escape digestion and absorption in the small bowel. These complex
polymers are then fermented to short-chain fatty acids (acetate, butyrate and propionate) and gases
(hydrogen (H2) and carbon dioxide (CO2)) [10].
In order to maintain fermentation, it is essential that H2 concentration is reduced by H2-consuming
microorganisms [11]. H2 can be used as an electron donor in sulfate respiration, methanogenesis
or acetogenesis to produce hydrogen sulfide (H2S), methane (CH4) and acetate, respectively [12].
Production of H2S is most favorable, followed by the production of CH4 and acetate, respectively.
However, for the production of H2S, the presence of sulfate is necessary [13]. The production of
CH4 is performed by archaea. Methanobrevibacter smithii (M. smithii) and Methanosphaera stadtmanae
(M. stadtmanae) are the two methanogens usually detected in the human gut. M. smithii is the
predominant methanogen in the human colon [14]. Next to H2,, formate can be used for the
methanogenesis as well [15]. The produced CH4 and the remaining H2 are excreted in breath and flatus.
Therefore, both gases can be measured in exhaled breath [13]. Measuring breath CH4 concentrations is
a simple way to investigate the metabolism of intestinal methanogens, since no significant catabolism
elsewhere in the human body has been observed [12]. The presence of M. smithii can be measured in the
feces, as has previously been performed in studies investigating patients suffering from inflammatory
bowel disease (IBD) [12,16].
The dysbiosis in RTRs may influence the fermentation in the gut and the processes following
fermentation, possibly leading to or contributing to posttransplant diarrhea. To gain more insight into
pathogenesis of this diarrhea, we aimed to investigate the fermentation and methanogenesis in the gut
in RTRs. Firstly, we aimed to investigate whether breath H2 and CH4 concentrations differ between
RTRs and HCs. Secondly, we aimed to investigate whether the presence of M. smithii in feces differs
between RTRs and HCs, and finally we aimed to identify the determinants of CH4 production.
2. Methods
2.1. Study Population
For this study we used data from the TransplantLines Biobank and Cohort Study (ClinicalTrials.gov
identifier: NCT03272841). A detailed description of the study design, inclusion and exclusion criteria
has been described previously [17]. In addition to the standard protocol, we measured breath H2 and
CH4 concentrations and analyzed the presence of M. smithii in feces for the current study. (Potential)
living organ donors were used as a healthy control group for comparison. Our inclusion period was
between February and December 2017. The study protocol has been approved by the Institutional
Review Board (METc 2014/077) (METc UMCG), adheres to the UMCG Biobank Regulation, and is in
accordance with the WMA Declaration of Helsinki and the Declaration of Istanbul [17].
2.2. Patient Comorbidities
Diabetes mellitus was defined according to the guidelines of the American Diabetes Association [18].
The estimated glomerular filtration rate (eGFR) was calculated using the serum creatinine-based chronic
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kidney disease epidemiology collaboration (CKD-EPI) formula. Data regarding the history of allograft
rejection and primary renal disease before transplantation were retrieved from patients’ medical files.
2.3. Breath H2 and CH4 Concentration Measurement
For H2 and CH4 measurements, breath samples were collected using a 50 cc syringe with an
opening of 6 mm in diameter at approximately 40 cc with a 3-way-stopcock. Subjects were instructed
to inhale normally and exhale fully in the syringe, with the plunger set at 50 cc and the 3-way stopcock
open. After full expiration, the opening was immediately closed by the subject’s finger, the plunger
was set to 30 cc and the 3-way stopcock was closed. This resulted in breath samples that were not
diluted by environmental air. Two breath samples were taken subsequently per study subject. Breath
samples were analyzed within 12 h after sample collection. H2, CH4 and CO2 measurements were
performed using a solid-state gas-chromatography device (Breathtracker SC, QuinTron Instrument
Company, Inc., Milwaukee, WI, USA). The device separates the components by the basic principle of
gas chromatography, using room air as the carrier gas, which is pumped through the system by an
internal circulating pump. H2 and CH4 are separated from all other reducing gases and from each
other, and are carried past a solid-state sensor [19]. The sensors are reported to be affected only by
reducing gases, so it is unaffected by other gases in the sample; it can also employ a CO2 correction
factor [19]. The analytical sensitivity is 1 ppm for H2 and CH4 and 0.1% for CO2. The Breathtracker
has a linear analytical range of 2–150 ppm for H2, 2–75 ppm for CH4 and 1000–70,000 ppm for CO2.
To ensure reliable breath measurements, study subjects were not allowed to smoke for at least one
hour before the sample collection [20].
2.4. M. Smithii Measurement in Feces
Fecal samples were collected the day prior to the TransplantLines visit, using a FecesCatcher
(TAG Hemi VOF, Zeijen, The Netherlands) and were immediately frozen after collection. The feces
samples were transported in cold storage to the TransplantLines visit, and immediately stored at −80 °C
(−112 ◦F) [17]. After thawing, DNA was extracted with the RBB and Qiagen method, as performed by
Yu et al. with modifications described by de Goffau et al. [21,22]. To measure the quantity of M. smithii,
real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) (7500 real time PCR
system, applied Biosystems, Thermo Fisher Scientific, Waltham, USA) was performed. Primers were
taken as described by Johnston et al., and differentiation between M. smithii and other organisms in
the sample was assessed using nifH genes [23]. The number of nifH genes are equal to the number of
M. smithii, since only one gene of nifH is present in each M. smithii [24]. Analyses were performed using
the Taqman machine and processed using SDSShell (Applied Biosystems, Thermo Fisher Scientific,
Waltham, USA). The quantifiable presence of M. smithii was determined using a cycle threshold value.
Values < 40 cycles were regarded as positive, and values ≥40 were regarded as negative. For analyses,
CT-values ≥40 were regarded as negative and concentrations of M. smithii in these patients were
regarded as 0 M. smithii/gram feces. A detailed method description is attached in Supplementary File 1.
2.5. Statistical Analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS)
version 23.0 (IBM corp.; Armonk, NY, USA). In all analyses, p < 0.05 was regarded as statistically
significant. Categorical variables are presented as n (%), normally distributed variables as mean
± standard deviation (SD) and non-normally distributed variables as median [interquartile range].
Normality was assessed using Q–Q plots. Differences between groups with normally distributed
variables were assessed using independent T-tests. Non-normally distributed data were compared
using the Mann–Whitney U test. Comparison of categorical variables was performed using a chi-square
test for groups with n ≥ 5 and a Fisher’s exact test for groups with n < 5. For all other tests and
visualizations, the mean of the duplicate measurements of the breath H2 and CH4 concentration
in breath was used. To correct for environmental CH4, 2 ppm was subtracted from each breath
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CH4-measurement [25,26]. Possible determinants of breath CH4 were identified using univariable
linear regression. All variables with a p-value <0.2 were included in a multivariable linear regression
model run backward to identify the determinants of breath CH4 production. Because H2 is used by
M. smithii for the conversion to CH4, an interaction term of H2 and M. smithii was added in the analysis.
Log10 transformations were performed if necessary to reach conditions in all performed analyses.
3. Results
We included 219 study subjects, of whom 142 (64.8%) were RTRs and 77 (35.2%) were HCs. Among
RTRs, 91 (64.1%) were male, and the mean age was 56.3 ± 13.7 years. Among HCs, 39 (50.6%) were
male, and the mean age was 56.4 ± 10.6 years. Baseline characteristics are shown in Table 1. A Consort
Flow diagram is presented to provide an overview of subgroups that were used in different analyses
(Figure 1). Breath H2 concentrations of the RTRs were not significantly different compared with HCs
(Table 1). The RTRs had, however, lower breath CH4 concentrations compared to the HCs (7.5 [3.9–10.6]
ppm vs. 16.0 [8.0–45.5] ppm, p < 0.001). Data distributions of breath H2 and CH4 concentrations are
shown in Supplementary File 2. Raw data are shown in the Supplementary data.
Table 1. Baseline characteristics.
Characteristics Renal TransplantRecipients Healthy Controls p-Value
Number of subjects, n (%) 142 (64.8) 77 (35.2) n/a
Fermentation parameters
Breath H2 concentration, ppm 11.3 [4.0–30.0] 10.5 [4.5–28.3] 0.9
Breath CH4 concentration, ppm 7.5 [3.9–10.6] 16.0 [8.0–45.5] <0.001
Quantifiable abundance of M. smithii in feces, n
(valid %) 22 (28.6) 38 (86.4) <0.001





[1.2 × 106–8.9 × 108] <0.001
Demographics
Age, y 56.3 ± 13.7 56.4 ± 10.6 0.6
Number of males, n (%) 91 (64.1) 39 (50.6) 0.05
BMI, kg/m2 28.0 ± 5.2 26.4 ± 3.8 0.01
Time since transplantation, y 1.0 [0.5–8.0] - n/a
Lifestyle parameters
Current smokers, n (valid %) 23 (16.7) 14 (18.9) 0.4
Alcohol intake per day, units 0.0 [0.0–0.2] 0.25 [0.0-0.5] 0.003
Laboratory parameters
Hemoglobin, g/dL 13.8 ± 1.9 14.4 ± 1.3 0.008
Hematocrit, L/L 0.42 ± 0.06 0.43 ± 0.04 0.2
Leukocytes, 109/L 7.4 ± 2.5 6.5 ± 1.9 <0.003
Platelets, 109/L 250.6 ± 78.4 261.2 ± 56.6 0.3
C-reactive protein, mg/L 2.3 [1.1–5.0] 1.2 [0.8–4.0] 0.035
Albumin, g/L 44.2 ± 3.1 45.4 ± 2.5 0.003
Glucose, mmol/L 6.0 ± 1.7 5.5 ± 0.7 0.005
HbA1c, mmol/mol 42.3 ± 7.8 36.9 ± 3.5 <0.001
eGFR, ml/min/1.73 m2 49.8 ± 16.5 69.3 ± 18.7 <0.001
Creatinine, µmol/L 130 [103.0–156.8] 92.0 [81.0–106.0] <0.001
Urea, mmol/L 9.4 ± 4.4 5.8 ± 1.6 <0.001
Medication use
Antibiotics, n (%) 37 (16.9) 0 (0.0) <0.001
Immunosuppressants, n (%)
Prednisolone, n (%) 140 (98.6) - n/a
Mycophenolate mofetil, n (%) 112 (78.9) - n/a
Tacrolimus, n (%) 102 (71.8) - n/a
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Table 1. Cont.
Characteristics Renal TransplantRecipients Healthy Controls p-Value
Cyclosporine, n (%) 14 (9.9) - n/a
Everolimus, n (%) 7 (4.9) - n/a
Azathioprine, n (%) 10 (7.0) - n/a
Statins, n (%) 70 (49.3) 8 (10.4) <0.001
Proton pump inhibitors, n (%) 108 (76.1) 0 (0.0) <0.001
Insulin, n (%) 11 (7.8) 0 (0.0) 0.009
Biguanides, n (%) 7 (4.9) 0 (0.0) 0.09
Macrogol, n (%) 8 (5.6) 1 (1.3) 0.200
Lactulose, n (%) 2 (1.4) 0 (0.0) 0.500
Loperamide, n (%) 1 (0.7) 0 (0.0) 1.000
Antidepressants, n (%) 16 (7.3) 4 (5.2) 0.4
Primary renal disease before transplantation
Unknown, n (%) 23 (16.2) - n/a
Inflammatory disease 55 (38.7)
Congenital and hereditary kidney disease, n (%) 41 (28.9) - n/a
Renal vascular disease, excluding vasculitis, n (%) 13 (9.2) - n/a
Diabetic nephropathy, n (%) 10 (7.0) - n/a
Others
Diabetes mellitus, n (%) 27 (19.0) 1 (1.3) <0.001
History of allograft rejection, n (%) 14 (9.9) - n/a
Data are presented as mean ± standard deviation (SD), median with interquartile ranges (IQRs) or number with
percentages (%). Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; CH4, methane;
H2, hydrogen; HbA1c, hemoglobin A1c; M. smithii, Methanobrevibacter smithii.
Figure 1. Consort flow diagram. Abbreviations: CH4, methane; H2, hydrogen;M. smithii,Methanobrevibacter
smithii.
3.1. M. Smithii in Feces
The feces of 98 study subjects was not available for analysis. M. smithii abundance was analyzed
in the feces samples of 77 RTRs and 44 HCs (i.e., 121 of 219 study subjects, see Figure 1). Among the
RTRs, 22 (28.6%) had quantifiable concentrations of M. smithii in their stool samples. Among HCs,
38 (86.4%) had quantifiable concentrations of M. smithii in their feces samples. The median abundance
of M. smithii in the feces of those study subjects was 5.9 × 107 [1.2 × 106–8.9 × 108] per gram feces.
A quantifiable concentration of M. smithii was significantly less frequently observed in RTRs compared
to HCs ((22 (28.6%) vs. 38 (86.4%) resp.; p < 0.001) (Table 1). In addition, the abundance of M. smithii
was positively correlated with breath CH4 concentrations (r = 0.69, p < 0.001).
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3.2. Determinants of Breath CH4
Determinants of breath CH4 were analyzed using linear regression analysis in all 219 study
subjects, and these results are presented in Table 2. Breath H2 and the presence of a quantifiable
abundance of M. smithii in feces were associated with higher breath CH4 concentrations (standardized
beta (st. β) 0.57, p < 0.001 and st. β 0.94, p < 0.001 resp.). A negative interaction was found between
both determinants on breath CH4 (st. β −0.51, p = 0.001), indicating that in the presence of M. smithii
the magnitude of the correlation between H2 and CH4 in breath decreases from overt to virtually
absent (r = 0.88, p < 0.001 vs. r = 0.09, p = 0.5 resp., Figure 2). In addition, the use of mycophenolate
mofetil was associated with a lower breath CH4 concentration (st. β −0.18, p = 0.014). The described
determinants explained 55.0% of the total variation in breath CH4 concentrations.





St. β p-Value St. β p-Value
A medical history of renal transplantation (yes vs. no) −0.42 <0.001
Fermentation parameters
Log10 Breath H2, ppm 0.32 <0.001 0.54 <0.001
Quantifiable abundance of M. smithii in feces (yes vs. no) 0.55 <0.001 0.95 <0.001
Interaction between log10 breath H2 and M. smithii in feces 0.48 <0.001 −0.51 0.001
Demographics
Age, y 0.07 0.3
Gender (yes vs. no) −0.02 0.7
BMI, kg/m2 −0.18 0.012
eGFR, mL/min/1.73 m2 0.25 <0.001
Intoxications
Smoking (yes vs. no) −0.10 0.1
Alcohol (units per day) −0.01 0.9
Medication use (yes vs. no)
Antibiotics −0.12 0.1
Immunosuppressive medication (yes vs. no)
Prednisolone −0.40 <0.001
Mycophenolate mofetil −0.36 <0.001 −0.18 0.014
Tacrolimus −0.27 <0.001
Cyclosporine −0.06 0.4
Azathioprine 0.00 1.0 −0.10 0.1
Everolimus 0.04 0.5
Statins −0.15 0.024




Biguanide drugs −0.04 0.6
Insulin −0.05 0.5
Antidepressants −0.14 0.044
Primary renal disease of RTR (yes vs. no)
Unknown −0.04 0.6
Inflammatory disease 0.02 0.8
Congenital and hereditary kidney disease 0.00 1.0
Renal vascular disease, excluding vasculitis 0.09 0.3
Diabetes Mellitus −0.08 0.3
Others (yes vs. no)
Suffering from Diabetes Mellitus −0.06 0.4
History of allograft rejection −0.02 0.8
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; CH4, methane; H2, hydrogen;
M. smithii, Methanobrevibacter smithii; St. β, standardized beta. R2 = 0.550. * Run backwards.
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Figure 2. Scatterplot of log10 breath H2 and CH4 concentration by presence of M. smithii in feces.
There is a difference between the relation between H2 and CH4 in subjects with and without M. smithii.
Abbreviations: CH4, methane; H2, hydrogen; M. smithii, Methanobrevibacter smithii. N = 121. Pearson
correlation in the absence of M. smithii, r = 0.88, p < 0.001. Pearson correlation in the presence of
M. smithii, r = 0.09, p = 0.5.
4. Discussion
We have shown that although no significant difference in breath H2 concentration was found
between RTRs and HCs, breath CH4 concentrations were significantly lower in the RTRs compared
with the HCs. In addition, we found a significantly lower presence of M. smithii in the feces of RTRs
compared with HCs. Breath H2 and the presence of M. smithii in feces were associated with higher
breath CH4 concentrations. Moreover, the association between breath H2 and CH4 concentrations
disappeared in presence of M. smithii in feces. Finally, mycophenolate mofetil was associated with a
lower breath CH4 concentration.
The reduced breath CH4 concentration in RTRs compared to HCs which we observed might
be explained by the reduced presence of M. smithii in the feces of RTRs, since M. smithii is the most
abundant methanogen in the human gut [12]. One reason for the lower prevalence of M. smithii in the
feces of RTRs may be the result of an increased presence or activity of sulfate-reducing bacteria (SRB).
It has been described that a high concentration of either methanogens or sulfate-reducing bacteria is
present in the feces of healthy individuals. These two groups of microorganisms appear to be competing
for H2, with the prevailing group becoming the predominant organism [27,28]. However, since no
mechanism of direct competition between SRB, methanogens and acetogens has been observed, at this
point it is impossible to predict any dominance of one of these hydrogenotrophs [29]. If the gut in RTRs
is more colonized with SRB, or if these SRB are more active, more hydrogen sulfide (H2S) is produced.
H2S is highly toxic to the colonocytes and impairs their metabolic function, especially the butyrate
oxidation [30]. Butyrate has a known anti-inflammatory effect and several other health-promoting
functions [31]. The presence of butyrate in the lumen and the oxidation by colonocytes are both
involved in the regulation of water and sodium absorption from the colon [30]. SRB and the consequent
disturbance of butyrate oxidation is believed to play a key role in the pathogenesis of IBD [12]. If SRB
are indeed more present in RTRs, this might also be an explanatory factor for the occurrence of any of
the gastrointestinal complaints of RTRs [16], especially since the butyrate concentration in RTRs seems
to be lower due to the reduced prevalence of bacteria taxa that produce butyrate [7].
In addition, more colonization with SRB, and consequently more H2S, may diminish the positive
effects of the butyrate in the gut of RTRs. However, the presence of SRB was not measured in this study.
Although our results regarding the decreased presence of M. smithii do support this hypothesis, future
studies will have to further test this hypothesis.
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Another reason for the lower prevalence of M. smithii in feces might be a lower presence of mucins
in the gut of RTRs. We observed no significant correlation between breath H2 and CH4 concentrations in
the presence of M. smithii. Therefore, the produced CH4 by M. smithii may be derived from endogenous
substrates such as mucins, formate or other unknown substrates [12,32]. Importantly, for mucins it has
not yet been settled whether they contribute to methane production or rather inhibit it, or under which
circumstances stimulation may shift towards inhibition [32,33]. Mucins cover the epithelium and form
a protective layer in the gut, thereby providing a protective layer against pathogenic organisms [34].
Deficiencies of mucin in the intestinal barrier are associated with an abnormal mucosal inflammatory
response, which is present in IBD [34]. The role of mucins in the fermentation processes in RTRs has,
to our best knowledge, never been investigated.
We also observed a strong correlation between breath H2 and CH4 concentrations in the absence
of M. smithii in feces (Figure 2). Possibly, other methanogens that flourish in the absence of M. smithii
are more dependent upon H2 concentrations. One of these methanogens might be M. stadtmanae,
an archaeon that is the second most common archaeon in the healthy gut after M. smithii [35]. It is
known that the CH4 production by M. stadtmanae is highly dependent upon the presence of H2
and methanol [36,37]. An increased prevalence of M. stadtmanae has been observed previously in
IBD patients in a study by Lecours et al. [38]. Interestingly, it has been reported that M. stadtmanae
can induce an inflammatory cytokine response from monocyte-derived dendritic cells, which may
contribute to pathological conditions in the gut [39]. In order to gain more insight into gut health in
RTRs, the prevalence of M. stadtmanae needs to be further investigated [12,39,40].
In addition, our study shows that patients using mycophenolate mofetil exhale lower
concentrations of CH4. Previous studies have shown that mycophenolate mofetil is associated
with gastrointestinal injury and diarrhea, although any underlying mechanisms are incompletely
understood [6]. Lower CH4 levels are also associated with diarrhea [12]. Future studies may investigate
whether methanogenesis plays a role in the association between mycophenolate mofetil and diarrhea.
Our observations are in line with previous studies in IBD patients [12,41]. This is interesting,
since RTRs and IBD patients have similarities: both groups suffer from intestinal dysbiosis, often have
diarrhea and often need to take immunosuppressive medication [38,42–44]. Scanlan et al. observed a
significantly lower presence of methanogen-positive feces samples in patients suffering from ulcerative
colitis compared to healthy controls (24% versus 48%). In addition, a lower presence of methanogens in
patients suffering from Crohn’s disease was observed (30% versus 48%), although this association was
not statistically significant [41]. In another study by Ghavami et al., significantly higher amounts of
M. smithii were found in the feces samples of HCs compared to IBD patients [16]. Our results suggest
that the reduced colonization with M. smithii, and possibly the methanogenesis of IBD patients, might
be comparable to RTRs.
It is known that CH4 reduces inflammation, oxidative stress and apoptosis in the human body [45].
Our findings show significantly lower breath CH4 concentrations in RTRs compared to HCs, while the
protective properties of CH4 appear especially important in RTRs in the context of (prevention of) renal
rejection, inflammation and high levels of oxidative stress [46]. Future studies may further investigate
the associations of (breath) CH4 concentrations with patient outcomes, such as renal rejection. If the
hypotheses regarding the protective properties of CH4 are confirmed, the relatively low CH4 levels in
RTR may be a therapeutic target, since CH4 concentrations in the body can be increased iatrogenically
by inhalation or injection [47,48].
No difference in breath H2 concentration was found in the current study. This is in line with other
studies: the matter of hydrogenotrophics in the gut is highly complex, and is dependent upon many
variables [49].
It is a limitation of our study that we did not measure mucin concentrations or potential
colonization by SRB or M. stadtmanae. In addition, we did not measure H2 and CH4 concentrations in
flatus, although it has been found that the concentration of both gases are higher in flatus than in breath
when the concentrations are high [50]. No data regarding menopausal status was available in our study,
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although it is known that menopausal status does affect the gut microbiome [51]. Additionally, we did
not measure breath H2 and CH4 concentrations and the abundance of M. smithii in the feces of RTRs
before transplantation. Further limitations of our study are that it was performed in a single center,
and that our RTRs were included at different time points after transplantation. Another limitation of
this study is that for logistical reasons we were unable to analyze M. smithii in the feces of all our study
subjects. In addition, although we measured the breath H2 concentrations in the morning, shortly after
breakfast, it was in a non-fasting state. Finally, the current study uses cross-sectional data, and therefore
no conclusions regarding causal relationships can be drawn.
5. Conclusions
To the best of our knowledge, this is the first study to investigate both breath and feces samples in
RTRs. The study shows that breath CH4 concentration and the prevalence of M. smithii in feces are
significantly lower in RTRs compared to HCs. Our findings regarding the altered methanogenesis
in the gut of RTRs show significant similarities with previous results in IBD patients. We observed
that in the absence of M. smithii, breath CH4 production is highly dependent on H2 concentration,
while this is not the case in the presence of M. smithii. Apparently, methanogenesis differs significantly
depending on presence of M. smithii. Finally, the use of mycophenolate mofetil was associated with
methanogenesis. These findings provide novel insight into the alterations of fermentation after renal
transplantation, which may contribute to the occurrence of posttransplant diarrhea. In addition,
this study has raised important hypotheses regarding the potential role of SRB and M. stadtmanae in
post-transplant diarrhea. Future studies are needed to investigate the role of SRB and M. stadtmanae.
Additionally, future research may study whether altered methanogenesis is associated with clinical
outcomes, such as posttransplant diarrhea.
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